Overview

A Study of Romiplostim for the Treatment of Refractory Transfusion-dependent NSAA

Status:
NOT_YET_RECRUITING
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
Efficacy and safety of Romiplostim in the treatment of refractory transfusion-dependent NSAA.
Phase:
PHASE4
Details
Lead Sponsor:
Peking Union Medical College Hospital
Treatments:
romiplostim